Merck's KEYTRUDA Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients with Renal Cell Carcinoma at an Increased Risk of Recurrence Following Nephrectomy

RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced results from the Phase 3 KEYNOTE-564 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for the adjuvant...

Related Keywords

Japan ,United States ,Canada ,American ,Nancy Kohlberg ,Tonik Choueiri ,Merck Research Laboratories ,Akeso Inc ,Asco Gu Press Program ,European Union ,Harvard Medical School ,Lank Center ,Dana Farber Cancer Institute ,American Society Of Clinical Oncology ,Clinical Oncology ,Cancers Symposium ,Genitourinary Oncology ,Farber Cancer Institute ,Positive Score ,News Publishing ,Markets ,